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Abstract
Background Sarcopenia frequently occurs in metastatic cancer patients. Emerging evidence has revealed that various secre-
tory products from metastatic tumours can inﬂuence host organs and promote sarcopenia in patients with malignancies. Fur-
thermore, the biological functions of microRNAs in cell-to-cell communication by incorporating into neighbouring or distal
cells, which have been gradually elucidated in various diseases, including sarcopenia, have been elucidated.
Methods We evaluated psoas muscle mass index (PMI) and intramuscular adipose tissue content (IMAC) using pre-operative
computed tomography imaging in 183 colorectal cancer (CRC) patients. miR-203 expression levels in CRC tissues and pre-
operative serum were evaluated using quantitative polymerase chain reaction. Functional analysis of miR-203 overexpression
was investigated in human skeletal muscle cells (SkMCs), and cells were analysed for proliferation and apoptosis. Expressions
of several putative miR-203 target genes (CASP3, CASP10, BIRC5, BMI1, BIRC2, and BIRC3) in SKMCs were validated.
Results A total of 183 patients (108men and 75women) were included. The median age of enrolled patients at diagnosis was
68.0 years (range 35–89 years). High IMAC status signiﬁcantly correlated with female gender (P = 0.004) and older age
(P = 0.0003); however, no other clinicopathological factors correlated with IMAC status in CRC patients. In contrast, decreased
PMI signiﬁcantly correlated with female gender (P = 0.006) and all well-established disease development factors, including ad-
vanced T stage (P = 0.035), presence of venous invasion (P = 0.034), lymphovascular invasion (P = 0.012), lymph node
(P = 0.001), distant metastasis (P = 0.002), and advanced Union for International Cancer Control tumour–node–metastasis stage
classiﬁcation (P = 0.0004). Although both high IMAC status and low PMI status signiﬁcantly correlated with poor overall survival
(IMAC: P = 0.0002; PMI: P < 0.0001; log-rank test) and disease-free survival (IMAC: P = 0.0003; PMI: P = 0.0002; log-rank test),
multivariate Cox’s regression analysis revealed that low PMI was an independent prognostic factor for both overall survival
(hazard ratio: 4.69, 95% conﬁdence interval (CI): 2.19–10, P = 0.0001) and disease-free survival (hazard ratio: 2.33, 95% CI:
1.14–4.77, P = 0.021) in CRC patients. Serum miR-203 expression negatively correlated with pre-operative PMI level
(P = 0.0001, ρ =0.25), and multivariate logistic regression analysis revealed that elevated serum miR-203 was an independent
risk factor for myopenia (low PMI) in CRC patients (odds ratio: 5.16, 95% CI: 1.8–14.8, P = 0.002). Overexpression of miR-203
inhibited cell proliferation and induced apoptosis via down-regulation of BIRC5 (survivin) expression in human SkMC line.
Conclusions Assessment of serum miR-203 expression could be used for risk assessment of myopenia, and miR-203might be
a novel therapeutic target for inhibition of myopenia in CRC.
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Introduction
Cancer cachexia is deﬁned as a ‘multi-factorial, systemic syn-
drome characterized by weight loss due to loss of skeletal
muscle mass (sarcopenia)’.1 Several lines of evidence have
suggested that alteration of muscle cell homeostasis via dete-
rioration and decreased synthesis of muscle proteins can pro-
mote muscle cell loss in patients with malignancies.2–4
Furthermore, a pattern of sarcopenia (myopenia and
myosteatosis) and this clinical burden as a feasible indicator
of poor prognosis in cancer patients is gradually eluci-
dated.5–8
Metastasis is the systemic dissemination of cancer cells
from the primary tumour site,9 and sarcopenia is com-
monly observed in advanced cancer patients with distant
metastases.10,11 A close link between metastasis and
sarcopenia has been demonstrated in various types of
cancers, including colorectal cancer (CRC).10,12,13 Further-
more, recent studies have revealed that various secretory
products, including soluble proteins, metabolites, and
exosomes, from metastatic tumours can inﬂuence host or-
gans and promote sarcopenia in patients with malignan-
cies.10,14,15 However, the detailed mechanism underlying
the development of sarcopenia in metastatic cancer pa-
tients remains unclear.
MicroRNAs (miRNAs) are a class of small single-stranded
RNAs approximately 18–25 nucleotides in length that are in-
volved in various essential biological processes, such as devel-
opment, cellular differentiation, proliferation, and
apoptosis.16–18 Exosome-encapsulated miRNAs are secreted
from various tissues and can stably exist in systemic circula-
tion. Recent studies have revealed the capability of these
miRNAs to exert biological functions by incorporating into
neighbouring or distal cells.19,20
A recent study from our research group demonstrated
that miR-203 (ofﬁcial name: miR-203a-3p, gene ID:
406986) is one of the most representative secretory
miRNAs in CRC patients and that circulating miR-203 origi-
nated from metastatic tissues, not primary cancerous tis-
sues.21 Furthermore, other studies demonstrated that
transient expression of miR-203 inhibits cell differentiation
in various types of cells, including skin cells and skeletal
muscle cells (SkMCs).22,23
In this study, we systemically assessed the clinical signif-
icance of pre-operative myopenia and myosteatosis in CRC
patients. We further evaluated the expression of the
metastasis-related miR-203 in primary tissues and
matched serum specimens from these patients to evaluate
the correlation between miR-203 expression and body
composition (BC) alteration in CRC patients. We also per-
formed a series of in vitro analyses using a human SkMC
line to clarify the biological role of miR-203 in the devel-
opment of sarcopenia in advanced cancer patients with
metastasis.
Material and methods
Patients
A total of 183 patients undergoing surgery for resection of
primary CRC tumours at Mie University Hospital were en-
rolled in this study. None of the patients received chemother-
apy or radiotherapy prior to surgery, and no peri-operative
mortality was observed. The median age of the patients at di-
agnosis was 68.0 years (range 35–89 years). The diagnosis of
CRC was conﬁrmed in all 183 patients based on clinicopatho-
logical ﬁndings. The tumour–node–metastasis staging system
from the American Joint Committee on Cancer was used for
the pathological tumour staging of CRC.24 The locations of
tumours and distant metastases were determined by barium
enema, colonoscopy, computed tomography (CT), and mag-
netic resonance imaging. Resection of the primary tumour
was performed in all patients, and all patients were followed
up for tumour recurrence at regular intervals for up to
5 years. During each annual hospital visit, all patients
underwent a chest X-ray, colonoscopy, and abdominal CT.
Patients treated with radiotherapy or chemotherapy before
surgery were excluded from this study. All patients were clas-
siﬁed according to Union for International Cancer Control
stage classiﬁcation of resected specimens: 37 patients had
Stage I disease, 61 had Stage II, 44 had Stage III, and 41 had
Stage IV. All CRC patients with Stage III/IV disease received
5-ﬂuorouracil-based chemotherapy, whereas no adjuvant
chemotherapy was given to Stage I and II patients. Patients
were observed at 3 month intervals for 24 months after com-
pletion of surgery, followed by every 6 months for 3 years
and then yearly. A history was taken, and a physical examina-
tion was performed at each visit, and chest X-ray, colonos-
copy, and CT were performed annually. All participants
provided informed written consent, and the study protocol
was approved by the Institutional Review Board of our
institution.
Image analysis
The height data of all patients were recorded, and pre-
operative CT scan was assessed within 4 weeks before sur-
gery. Pre-operative CT scan images were stored in an elec-
tronic format suitable for image analysis to assess the BC
status. Using pre-operative plain CT at superior aspect of
the fourth lumbar vertebra as previously described,13,25,26
we measured the cross-sectional area of the bilateral psoas
muscles by manual tracing, and then the psoas muscle mass
index (PMI) was calculated as follows: PMI = cross-sectional
area of bilateral psoas muscle height2 (cm2/m2). Low PMI
was regarded as a proxy for low muscle volume, as previously
described.6–8 Subfascial muscular tissue in the multiﬁdus
muscle was estimated by manual tracing at the same level
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on pre-operative plain CT images, and mean CT values
[Hounsﬁeld unit (HU)] for these areas were determined with
the Aquarius NET server (Tera Recon, Inc., San Mateo, CA,
USA). We placed four circles on areas of subcutaneous fat
away from major vessels in CT images that were used as
the region of interest (ROI) of subcutaneous fat. The mean
CT values (HU) for the ROI of subcutaneous fat were also
measured. Intramuscular adipose tissue content (IMAC) was
calculated by the ratio of these CT values, as previously re-
ported by Kitajima et al.,27,28 as follows: IMAC = mean CT
value of ROI of multiﬁdus muscle (HU) mean CT value of
ROI of subcutaneous fat (HU). High IMAC was regarded as a
proxy for low muscle quality.
Sample collection
We obtained surgical tissue specimens and matched pre-
operative serum specimens from CRC patients in this study.
All of these patients were previously described as a validation
cohort in a biomarker study of serum miR-203.21 Blood sam-
ples were obtained by venipuncture before surgery. Each
sample was centrifuged at 3000 × g for 5 min and stored at
80 °C until analysis.
RNA isolation and quantitative reverse
transcription polymerase chain reaction from
serum samples
RNA extraction and miRNA enrichment from all serum samples
were performed using the Qiagen miRNeasy Kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s instruc-
tions. Brieﬂy, 200 μL of serum was thawed on ice and centri-
fuged at 3000 × g for 5 min to remove cell debris. Next,
200 μL of the supernatant was lysed in 5 volumes of Qiazol so-
lution. To normalize any inadvertent sample-to-sample varia-
tions during the RNA isolation procedure, reverse
transcription (RT), and PCR, 25 fmol of synthetic Caenorhabditis
elegansmiRNA (cel-miR-39) was added to each denatured sam-
ple. Small RNAs were then enriched and puriﬁed following the
manufacturer’s protocol, with the exception that the enriched
small RNAs were eluted in 40 μL of nuclease-free water. For
miRNA-based RT–PCR assays, 1.67 μL of enriched small RNAs
from serum or cell culture medium were reverse transcribed
using the TaqManMicroRNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA) in a total volume of 5 μL, ac-
cording to the manufacturer’s instructions. A 1:15 dilution of
the RT products was used as template for the PCR. PCRs for
quantifying miR-203 and cel-miR-39 were performed in dupli-
cate, with TaqMan 2× Universal PCR Master Mix, using condi-
tions previously described.29,30
RNA isolation and quantitative reverse
transcription polymerase chain reaction from
formalin-ﬁxed, parafﬁn-embedded tissues
Total RNA was isolated from formalin-ﬁxed, parafﬁn-
embedded samples using the RecoverAll Total Nucleic Acid
Isolation Kit (Ambion Inc., Austin, TX, USA) according to the
manufacturer’s instructions. Brieﬂy, tissue sections were mi-
crodissected to enrich for neoplastic cells, followed by
deparafﬁnization and RNA extraction using the manufac-
turer’s protocol. Total RNA was eluted in the appropriate
buffer and quantiﬁed using a NanoDrop Spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA). RT reactions
were carried out using the TaqMan MicroRNA Reverse Tran-
scription Kit (Applied Biosystems, Foster City, CA, USA) in a
total reaction volume of 15 μL. MiR-16 was chosen as the en-
dogenous normalizer for miRNAs based on previous ﬁndings
that miR-16 is one of the most suitable reference genes for
relative quantiﬁcation of small non-coding RNAs in colonic tis-
sues including with CRC and normal colonic mucosa from mi-
croarray analysis of large cohorts; in addition, we previously
demonstrated that miR-16 is a reliable normalizer for tissue
samples.21,30–35 MiR-203 and miR-16 were quantiﬁed by
quantitative reverse transcription polymerase chain reaction
(qRT–PCR) using MicroRNA Assay Kits (Applied Biosystems)
in duplicate reactions. qRT–PCR was performed on an Applied
Biosystems 7000 Sequence Detection System with the follow-
ing cycling conditions: 95 °C for 10 min, followed by 45 cycles
of 95 °C for 15 s and 60 °C for 1 min. Cycle threshold (Ct)
values were calculated using the same threshold cut-off
values for each assay to prevent plate-to-plate variations.
Data were analysed using the SDS 1.4 software (Applied
Biosystems, Foster City, CA, USA). PCRs for quantifying miR-
203 and miR-16 were performed in duplicate reactions with
TaqMan 2× Universal PCR Master Mix.
Calculation of microRNA expression
Expression levels of miRNAs were normalized using cel-miR-
39 (for serum samples) and miR-16 (for tissue samples) using
the 2–ΔCt method, as previously described.21,30–32,34,35 Differ-
ences between the groups are presented as ΔCt, indicating
differences between Ct values of miRNAs of interest and Ct
values of normalizer miRNAs.
Cell line
The human SkMC line was purchased from Promo Cell
(Heidelberg, Germany) and maintained in Skeletal Muscle Cell
Growth Medium (Promo Cell) at 37 °C in 5% humidiﬁed CO2
atmosphere.
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Transfection of miR-203 mimic molecules
To induce miR-203 expression, cells were transfected with
mirVana hsa-miR-203-3p mimic (miR-203 mimic, Applied
Biosystems) using Lipofectamine 2000 (Invitrogen). A
mirVana miRNA mimic negative control (Applied Biosystems)
containing a random sequence with no identiﬁable effects
on functions of known miRNAs was used as a negative
control. The ﬁnal oligonucleotide concentration was 50 nM.
Cells were transfected for 48 h before analysis.
Cell proliferation assay
Cell proliferation was evaluated with a WST-8 colorimetric
assay kit (Cell Counting Kit-8, Dojindo Laboratories, Tokyo,
Japan). Forty-eight hours after transfection of SkMCs with
miR-203 mimic or negative control mimic, cells were
seeded at 5 × 103 cells per well in 96-well ﬂat-bottomed
microtitre plates in a ﬁnal volume of 100 μL culture me-
dium per well and incubated in a humidiﬁed atmosphere.
After 0–7 days of culture, 10 μL Cell Counting Kit-8 reagent
was added to each well, and the plates were incubated for
1 h in a humidiﬁed atmosphere. The absorbance of each
well was measured at a wavelength of 450 nm using
SoftMax Pro (Molecular Devices Corp., Sunnyvale, CA,
USA). Each independent experiment was performed
three times.
Cell cycle analysis and apoptosis assay
For cell cycle analysis, the DNA content of miR-203 mimic-
transfected or negative control mimic-transfected SkMCs
was evaluated using the MuseTM cell cycle assay kit
(Millipore, Billerica, MA, USA), according to the manufac-
turer’s instructions, on the Muse Cell Analyzer (Millipore).
Each independent experiment was performed three times.
The rate of apoptosis was measured in transfected cells using
the annexin V and Dead Cell Assay Kit (Millipore) and the
WST-8 colorimetric assay (Cell Counting Kit-8, Dojindo
Laboratories) following the manufacturers’ instructions.
Total RNA extraction, complementary DNA
synthesis, and quantitative reverse transcription
polymerase chain reaction
Total RNA was isolated using the miRNeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions. Complementary
DNA was synthesized from 5 μg total RNA with random
hexamer primers and SuperScript III Reverse Transcriptase
(Invitrogen, Carlsbad, CA, USA). qRT–PCR analysis was per-
formed using the StepOne Real-Time PCR System (Applied
Biosystems), as previously described.36,37 CASP3, CASP10,
BIRC5, BMI1, BIRC2, BIRC3, and GAPDH mRNA expression
levels weremeasured using Power SYBRGreenMasterMix (Life
Technologies, Carlsbad, CA, USA). Primers for CASP3, CASP10,
BIRC5, BMI1, BIRC2, BIRC3, and GAPDH mRNAs were designed
using PRIMER3 software (Biology Workbench Version 3.2; San
Diego Supercomputer Center, University of California, San
Diego, CA, USA). Sequence information of these primers is de-
scribed in Table S1.
Immunoﬂuorescence
Primary antibody for BIRC5 (1:50, Santa Cruz, Dallas, TX, USA)
was incubated overnight at 4 °C. After washing the sections ﬁve
times for 5 min, Alexa Fluor 546 goat anti-mouse IgG (1:100,
Invitrogen, Renfrew, UK) was used as the secondary antibody,
and was incubated for 1 h at room temperature. Nuclear stain-
ing was performed with 4,6-diamidino-2-phenylindole
dihydrochloride (DAPI) (ProLong Gold Antifade Reagent with
DAPI; Invitrogen). Confocal images were acquired by IX71
inverted microscopy with a DP70 digital camera system
(Olympus, Center Valley, PA, USA), as previously described.37
Statistical methods
Statistical analysis was performed using MEDCALC version
16.8.4 (MedCalc Software, Ostend, Belgium). Results are
expressed as medians ± interquartile ranges. Differences be-
tween groups were estimated by the χ2 test, one-way analy-
sis of variance, and Mann–Whitney U test when appropriate.
Shapiro–Wilk tests were performed to evaluate the normality
of distribution, and Levene’s tests were conducted to assess
the equality of variance for comparable groups. Correlations
between BC status and tissue or serum miR-203 expression
were assessed using Spearman’s rank correlation test. For
time-to-event analyses, survival estimates were calculated
using Kaplan–Meier analysis, and groups were compared with
the log-rank test. Receiver operating characteristic (ROC)
curves with Youden’s index were established to determine
the cut-off values for analysing prognosis in each gender.
Overall survival (OS) was measured from the date the patient
underwent surgery until the date of death resulting from any
cause (i.e. cancer-unrelated deaths were not censored) or last
known follow-up for patients that were still alive. Disease-
free survival (DFS) analysis was measured from the date the
patient underwent curative surgery to the date of disease re-
currence, death from any cause (i.e. cancer-unrelated deaths
were not censored), or until last contact with the patient.
Cox’s proportional hazard models were used to estimate haz-
ard ratios (HRs) for death and recurrence. Assumptions of
proportionality were conﬁrmed for the Cox proportional haz-
ards analyses by generating Kaplan–Meier survival curves
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(e.g. high vs. low PMI groups) and by ensuring that the two
curves did not intersect each other. Multivariate logistic re-
gression models were used to predict factors inﬂuencing
myopenia (low PMI). Variables with P< 0.05 in the univariate
analysis were included in the multivariate analysis. Clinical
variables that were considered for univariate and multivariate
analyses, in addition to target BC status, were previously
identiﬁed confounding factors that affected the prognosis of
patients with CRC: sex, age at diagnosis, pathological differen-
tiation (differentiated or undifferentiated), T stage (T1/2 or
T3/4), venous invasion (present or absent), lymphatic vessel
invasion (present or absent), lymph node metastasis (present
or absent), and distant metastasis (present or absent). Fur-
thermore, we included representative nutrition markers, in-
cluding haemoglobin (high or low), number of lymphocytes
(high or low), and albumin (high or low) in multivariate logis-
tic regression analysis to identify independent risk factor for
myopenia in CRC patients. Cut-off thresholds for each covar-
iate were determined by ROC analysis with Youden’s index
for myopenia in each gender of CRC patients. All P values
were two sided, and those less than 0.05 were considered
statistically signiﬁcant.
Results
Differences of body composition status according
to sex
Based on previous ﬁndings about the gender-related differ-
ences of BC status in CRC patients, we ﬁrst assessed the rela-
tionships between sex and pre-operative BC status in CRC
patients (Table S2).6–8,13 In consistent with the previous re-
ports, both PMI and IMAC showed signiﬁcant differences be-
tween male and female CRC patients (PMI: 291.3 ± 130.6 and
215.9 ± 70.7, respectively, P < 0.00001; IMAC: 0.35 ± 0.2
and 0.24± 0.22, respectively, P = 0.00002). We thus set
the cut-off values for PMI and IMAC using sex-speciﬁc cut-
off values established by ROC curve analysis with Youden’s in-
dex for survival in this cohort (male, PMI: 240.8, IMAC:
0.26; female, PMI: 215.9, IMAC: 0.21).
Low pre-operative psoas muscle mass index is
signiﬁcantly correlated with clinicopathological
factors associated with disease progression in
colorectal cancer patients
We next evaluated the association between pre-operative
BC status and clinicopathological factors in CRC patients
(Table 1). High IMAC status signiﬁcantly correlated with
older age and female gender; however, no other oncological
clinicopathological factors were correlated with IMAC status in
CRC patients. In contrast, low PMI status signiﬁcantly correlated
with all well-established disease development factors, including
advanced T classiﬁcation (P = 0.035), presence of vessel
(P = 0.034), lymphovascular invasion (P = 0.012), lymph node
(P = 0.001), distant metastasis (P = 0.002), and advanced Union
for International Cancer Control tumour–node–metastasis
stage classiﬁcation (P = 0.0004) in CRC patients.
Decreased psoas muscle mass index in
pre-operative status is an independent prognostic
factor for both overall survival and disease-free
survival in colorectal cancer patients
We next conducted time-to-event analysis to clarify the prog-
nostic impact of pre-operative PMI and IMAC status in CRC
patients. We generated Kaplan–Meier survival curves accord-
ing to PMI and IMAC status. Interestingly, both high IMAC
and low PMI status signiﬁcantly correlated with poor progno-
sis for OS and DFS in CRC patients (IMAC: P = 0.0002 and
P = 0.0003, respectively, Figure 1A and 1B; PMI: P < 0.0001
and P = 0.0002, respectively, Figure 1C and 1D; log-rank test).
Furthermore, the prognostic impacts of pre-operative PMI
and IMAC were consistent in both male gender and female
gender in this cohort (Figure S1A–S1H).
To determine the potential of pre-operative BC status as a
predictive biomarker of recurrence and prognosis in CRC pa-
tients, we next performed multivariate Cox’s regression analysis.
In addition to lymph nodemetastasis and distant metastasis, low
pre-operative PMI was also an independent prognostic factor for
OS in CRC patients (HR: 4.69, 95% conﬁdence interval (CI): 2.19–
10, P = 0.0001, Table 2A). Furthermore, in addition to lymph
node metastasis, low pre-operative PMI was also an indepen-
dent prognostic factor for poor DFS in these patients (HR: 2.33,
95% CI: 1.14–4.77, P = 0.021, Table 2B).
Dysregulated miR-203 expression in tissue and
serum of colorectal cancer patients
We recently revealed that circulating miR-203 originated
from metastatic tissues, not primary cancerous tissues.21
Combined these evidences with functional role of miR-203
in cell differentiation of SkMCs,22,23 we thus next evaluated
tissue and matched pre-operative serum miR-203 expression
to clarify the association between miR-203 expression levels
and pre-operative BC status in CRC patients. Pre-operative
IMAC status was not associated with tissue or serum miR-
203 expression in CRC patients (Figure 1E). In contrast, the as-
sociation between PMI status and miR-203 expression dem-
onstrated engaging ﬁndings. miR-203 expression in primary
cancerous tissues was signiﬁcantly decreased in low PMI pa-
tients compared with those in high PMI patients (P = 0.03,
Figure 1F). On the other hand, pre-operative serum miR-203
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expression showed an opposite trend and was signiﬁcantly in-
creased in low PMI patients compared with high PMI patients
(P = 0.014, Figure 1F). Furthermore, to elucidate the direct
correlation in each of these levels, we used Spearman’s rank
correlation test and found that IMAC levels were not corre-
lated with tissue or serum miR-203 expression in CRC patients
(Figure 1G). Surprisingly, despite the lack of signiﬁcant corre-
lation between PMI status and miR-203 expression in cancer
tissues, serum miR-203 expression was negatively correlated
with pre-operative PMI in CRC patients (P = 0.001,
ρ = 0.25, Figure 1H).
Elevated miR-203 level in pre-operative serum was
an independent risk factor for myopenia in
colorectal cancer patients
During the last decade, various blood-based markers, such as
haemoglobin, lymphocytes, and albumin, have been shown as
potential analytes for the assessment of nutrition status and
myopenia in patients with various malignancies.38,39 In line with
previously published evidence, our cohort also demonstrated
that both pre-operative haemoglobin and albumin levels were
signiﬁcantly decreased in CRC patients with low vs. high PMI
(Figure S2A–S2C). To determine the potential of serum miR-
203 as a predictive biomarker for myopenia, we next performed
multivariate logistic analysis including these representative
blood-basedmarkers in CRC patients. Notably, in addition to de-
creased haemoglobin and albumin, elevated serum miR-203
levels emerged as one of the independent predictive factors
for myopenia (odds ratio: 5.16, 95% CI: 1.8–14.8, P = 0.002,
Table 3) in these patients. Collectively, these results suggest
that serummiR-203 expression may serve as a clinically feasible
biomarker for predicting cancer myopenia in CRC patients.
Therefore, we decided to perform further assessment of the
potential biological function of miR-203 in myopenia.
Overexpression of miR-203 inhibits cell
proliferation and promotes apoptosis in human
skeletal muscle cells
As described earlier, we found that elevated expression of cir-
culating miR-203 was negatively correlated with decreased
Table 1 Correlation between clinicopathological variables and PMI and IMAC in colorectal cancer patients
Variable n
PMI
P value
IMAC
P valueHigh (n = 112) Low (n = 71) High (n = 52) Low (n = 131)
Gender
Male 108 75 33 0.006* 22 86 0.004*
Female 75 37 38 30 45
Age (years)
≧68a 95 63 32 0.14 16 79 0.0003*
>68 88 49 39 36 52
Histological type
Differentiated 167 105 62 0.13 47 120 0.79
Undifferentiated 16 7 9 5 11
Location
Right 58 31 27 0.14 20 38 0.22
Left 125 81 44 32 93
Pathological T category
pT1/2 58 42 16 0.035* 13 45 0.22
pT3/4 125 70 55 39 86
Vessel invasion
Present 75 39 36 0.034* 27 48 0.06
Absent 108 73 35 25 83
Lymphovascular invasion
Present 136 76 60 0.012* 43 93 0.1
Absent 47 36 11 9 38
Lymph node metastasis
Present 76 36 40 0.001* 26 50 0.14
Absent 107 76 31 26 81
Distant metastasis
Present 40 16 24 0.002* 14 26 0.3
Absent 143 96 47 38 105
UICC TNM classiﬁcation
Stage I 37 29 8 0.0004* 9 28 0.17
Stage II 61 41 20 14 47
Stage III 44 25 19 15 29
Stage IV 41 17 24 14 27
IMAC, intramuscular adipose tissue content; PMI, psoas muscle mass index; TNM, tumour–node–metastasis; UICC, Union for International
Cancer Control.
aThe median age at surgery in this cohort was 68 years.
*P < 0.05. Bold font means signiﬁcant p-value in these tables.
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Figure 1 Prognostic impact of body composition (BC) status and its correlation with tissue or serum miR-203 expression in colorectal cancer (CRC)
patients (A–D). Prognostic impact of psoas muscle mass index (PMI) and intramuscular adipose tissue content (IMAC) in CRC patients. Kaplan–Meier
survival curves for overall survival (OS) (A, C) and disease-free survival (DFS) (B, D) in CRC patients based on IMAC or PMI status in CRC patients. High
IMAC status was signiﬁcantly correlated with poor prognosis in OS (P = 0.0002; log-rank test, A) and DFS (P = 0.0003; log-rank test, B). Decreased PMI
signiﬁcantly correlated with poor prognosis for OS (P < 0.0001; log-rank test, C) and DFS (P = 0.0002; log-rank test, D). (E, F) MiR-203 expression in
primary CRC tissues and pre-operative serum specimens according to BC status. (E, F) Association between tissue and serum miR-203 expression
and BC status in CRC. (E) MiR-203 expression in primary CRC tissues (left, P = 0.73) and pre-operative serum specimens (right, P = 0.83) was not sig-
niﬁcantly associated with IMAC status in CRC patients. (F) Decreased miR-203 expression in primary CRC tissues (left, P = 0.03) and elevated miR-203
expression in pre-operative serum (right, P = 0.014) were signiﬁcantly associated with low PMI status in CRC patients. Statistically signiﬁcant differences
were determined using the Mann–Whitney U test. Cut-off thresholds of PMI/IMAC were determined by receiver operating characteristic analysis with
Youden’s index for prognosis. (G, H) Direct correlation between tissue or serum miR-203 expression and BC level in CRC patients. (G) MiR-203 expres-
sion in primary CRC tissues (left, P = 0.3) and pre-operative serum specimens (right, P = 0.73) did not signiﬁcantly correlate with IMAC status in CRC
patients. (H) No signiﬁcant correlation was found between PMI level and miR-203 expression in CRC tissues (left), but serum miR-203 expression was
negatively correlated with PMI level in CRC patients (right, P = 0.001, ρ = 0.25). Statistically signiﬁcant differences were determined using the
Spearman’s rank correlation test, and all statistical tests were two sided.
542 Y. Okugawa et al.
Journal of Cachexia, Sarcopenia and Muscle 2019; 10: 536–548
DOI: 10.1002/jcsm.12403
skeletal muscles mass (decreased PMI) in CRC patients. We
thus next examined the potential functional role of miR-203
in myopenia in CRC patients. To investigate the function of
miR-203 in human SkMCs, we transfected miR-203 mimic
and miRNA negative control mimic into SkMCs and conﬁrmed
increased miR-203 levels in the miR-203 mimic-transfected
cells (Figure 2A). We ﬁrst evaluated the impact of miR-203 ex-
pression on cell proliferation using MTT assays in transfected
cells. Proliferation of SkMCs was moderately suppressed
7 days after miR-203 mimic transfection compared with neg-
ative control-transfected cells (Figure 2B). Further, cell cycle
analysis revealed that the G0/G1-phase fraction was slightly
increased after miR-203 overexpression (Figure 2C). We next
examined whether miR-203 overexpression affects apoptosis
in human SkMCs. Because of the highlight of this miR-203
function in SkMCs, we examined cell apoptosis using two
methods. Flow cytometry after annexin V and 7-amino-
actinomycin D staining demonstrated that SkMCs transfected
with miR-203 mimic showed a signiﬁcantly increased apopto-
sis rate compared with negative control-transfected cells
(P < 0.001, Figure 2D). Furthermore, we also used MTT assay
to evaluate the number of viable SkMCs and found a signiﬁ-
cant decrease of viable cells in SkMCs transfected with miR-
203 compared with negative control-transfected cells
(P < 0.001, Figure 2E).
Identiﬁcation of BIRC5 as target of miR-203 in
skeletal muscle cells
To elucidate the molecular mechanisms underlying the cellu-
lar effects of miR-203 in SkMCs, especially apoptosis, we
searched for potential gene targets of miR-203. Candidate
targets were ﬁrst determined using target prediction engines,
including miRMap, Microt4, TargetScan, and RNAhybrid, and
the overlapping candidate genes from these four prediction
Table 2A Multivariate analysis for predictors of overall survival
Variable
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Gender (male) 0.7 0.39–1.23 0.21
Age (>68 years old)a 1.43 0.81–2.53 0.21
Histological type (undifferentiated) 3.1 1.45–6.63 0.004* 2.16 0.94–4.95 0.07
Location (left) 0.68 0.38–1.22 0.2
T classiﬁcation (pT3/4) 4.8 1.9–12.1 0.0009* 2.6 0.91–7.39 0.07
Vessel involvement (present) 2.42 1.35–4.33 0.003* 0.67 0.32–1.43 0.3
Lymphatic vessel involvement (present) 3.24 1.28–8.19 0.013* 1.08 0.36–3.22 0.89
Lymph node metastasis (present) 4.49 2.43–8.31 <0.0001* 2.42 1.16–5.06 0.019*
Distant metastasis (present) 5.45 3.03–9.79 <0.0001* 3.02 1.51–6.02 0.002*
PMI (low)b 7.39 3.67–14.9 <0.0001* 4.69 2.19–10 0.0001*
IMAC (high)b 2.87 1.61–5.12 0.0003* 1.13 0.58–2.19 0.73
CI, conﬁdence interval; HR, hazard ratio; IMAC, intramuscular adipose tissue content; PMI, psoas muscle mass index.
aThe median age at surgery in this cohort was 68 years.
bCut-off thresholds of PMI/IMAC were determined by receiver operating characteristic analysis with Youden’s index for overall survival in
colorectal cancer patients.
*P < 0.05. Bold font means signiﬁcant p-value in these tables.
Table 2B Multivariate analysis for predictors of disease-free survival
Variable
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Gender (male) 0.79 0.41–1.52 0.49
Age (>68 years old)a 1.02 0.53–1.95 0.95
Histological type (undifferentiated) 2.76 1.15–6.62 0.023* 1.11 0.42–2.91 0.83
Location (left) 0.81 0.41–1.61 0.55
T classiﬁcation (pT3/4) 4.08 1.59–10.5 0.004* 2.22 0.73–6.72 0.16
Vessel involvement (present) 2.6 1.35–4.99 0.004* 1.29 0.59–2.81 0.52
Lymphatic vessel involvement (present) 3.05 1.19–7.84 0.021* 1.09 0.34–3.49 0.88
Lymph node metastasis (present) 3.83 1.99–7.35 0.0001* 2.51 1.23–5.15 0.012*
PMI (low)b 3.28 1.7–6.34 0.0004* 2.33 1.14–4.77 0.021*
IMAC (high)b 3.16 1.64–6.1 0.0006* 2 0.96–4.2 0.06
CI, conﬁdence interval; HR, hazard ratio; IMAC, intramuscular adipose tissue content; PMI, psoas muscle mass index.
aThe median age at surgery in this cohort was 68 years.
bCut-off thresholds of PMI/IMAC were determined by receiver operating characteristic analysis with Youden’s index for disease-free sur-
vival in colorectal cancer patients.
*P < 0.05. Bold font means signiﬁcant p-value in these tables.
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engines were selected for analyses. Based on our in vitro ex-
periments indicating a role for miR-203 in apoptosis, we fo-
cused the apoptosis pathway-associated genes among the
overlapping gene pool, especially CASP3, CASP10, BIRC5
(survivin), BMI1, BIRC2, and BIRC3 (Figure 2F). We examined
the expression proﬁles of these six genes in SkMCs
transfected with miR-203 mimic transfection or negative con-
trol. Among all six examined genes, only BIRC5 expression
was drastically decreased in miR-203 mimic-transfected cells
compared with negative control cells (Figure 2G). Further-
more, ﬂuorescent immunocytochemistry clearly revealed that
the protein expression of BIRC5 was also down-regulated in
miR-203 mimic-transfected cells (Figure 2H). This result is
consistent with a recent study that revealed the regulatory
interaction between miR-203 and the 30 untranslated region
of BIRC5 mRNA in HEK293T cells using luciferase assays.40
BIRC5 (survivin) is a member of the apoptosis inhibitor pro-
tein family and could suppress apoptosis via inhibition of
the initiator caspase 9 and executioner caspase 3 and 7.41
In addition, survivin has the potential role as a regulator of
cell division especially in G1/S arrest of the cell cycle.
42 Taken
together, these results successfully validated the clinical ﬁnd-
ing of a negative correlation between circulating miR-203 ex-
pression and pre-operative PMI levels. Our data suggest that
elevated expression of circulating miR-203 from metastatic
tissues might be involved in myopenia by inducing apoptosis
of SkMCs via inhibition of survivin in CRC patients.
Discussion
Sarcopenia is a progressive decline of skeletal muscle mass,
quality, and strength in response to various factors, including
ageing, lifestyle habits, inactivity, and chronic disease.43
Although accumulating evidence has demonstrated high
prevalence of sarcopenia in cancer patients with metasta-
sis,10,12,13 the detailed mechanism that drives sarcopenia is
not fully understood. We investigated whether alteration of
BC could correlate with the circulating metastasis-related
miRNA miR-203 in CRC patients, and our study presents sev-
eral novel ﬁndings. First, we systematically investigated pre-
operative BC status in CRC patients and demonstrated that
both decreased PMI and increased IMAC were signiﬁcantly
correlated with poor prognosis of OS and DFS in CRC patients.
In particular, decreased PMI was signiﬁcantly correlated with
all well-established clinicopathological factors for CRC devel-
opment and was an independent prognostic marker for OS
and DFS in CRC patients. Second, miR-203 expressions in pri-
mary CRC tissue and matched serum specimens were evalu-
ated, and we found that serum miR-203 expression, but not
tissue miR-203 expression, was negatively correlated with
pre-operative PMI in CRC patients. Furthermore, multivariate
logistic regression analysis revealed that elevated serum miR-
203 was an independent risk factor for low PMI (myopenia) in
CRC patients. These ﬁndings combined with previous evi-
dence from our group21 suggest that skeletal muscle might
be decreased in metastatic CRC patients by circulating miR-
203 released from metastatic tissues. We performed a series
of in vitro analyses and conﬁrmed that miR-203 overexpres-
sion signiﬁcantly promoted apoptosis in human SkMCs, possi-
bly through its down-regulation of survivin.
A high prevalence of sarcopenia in metastatic cancer pa-
tients is well documented.13,26 Although several factors, such
as anorexia due to organ dysfunction by distant metastasis,
adverse effect of systemic chemotherapy, deterioration of
physical activity, and psychological factors for disease devel-
opment, can induce sarcopenia in patients, emerging evi-
dence has suggested that sarcopenia may develop because
of secretory products from metastatic tissues in various
Table 3 Multivariate analysis for predictors of myopenia in CRC patients
Variable
Univariate Multivariate
OR 95% CI P value OR 95% CI P value
Gender (female) 2.33 1.27–4.3 0.007* 2.5 1.13–5.53 0.024*
Age (>68 years old)a 1.57 0.86–2.85 0.14
Histological type (undifferentiated) 0.46 0.16–1.29 0.14
Location (left) 0.62 0.33–1.17 0.14
T classiﬁcation (pT3/4) 2.06 1.04–4.05 0.036* 1.07 0.41–2.79 0.89
Vessel involvement (present) 1.93 1.05–3.53 0.034* 0.75 0.3–1.88 0.54
Lymphatic vessel involvement (present) 2.58 1.21–5.5 0.014* 1.97 0.62–6.26 0.25
Lymph node metastasis (present) 2.72 1.47–5.04 0.001* 1.71 0.72–4.07 0.22
Distant metastasis (present) 3.06 1.49–6.31 0.002* 1.42 0.5–4.07 0.51
Pre-operative haemoglobin (low)b 4.11 2.18–7.77 <0.0001* 3.1 1.36–7.08 0.007*
Pre-operative lymphocytes (low)b 0.55 0.27–1.09 0.09
Pre-operative albumin (low)b 4.69 2.44–9.02 <0.0001* 3.21 1.36–7.58 0.008*
Pre-operative serum miR-203 (high)b 5.46 2.32–12.8 0.0001* 5.16 1.8–14.8 0.002*
CI, conﬁdence interval; CRC, colorectal cancer; OR, odds ratio.
aThe median age at surgery is 68 years in CRC patients.
bCut-off thresholds of each covariate were determined by receiver operating characteristic analysis with Youden’s index for myopenia in
each gender of CRC patients.
*P < 0.05. Bold font means signiﬁcant p-value in these tables.
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Figure 2 Series of in vitro analysis using human skeletal muscle cells (SkMCs). (A) Overexpression of miR-203 expression 48 h after transfection in
SkMC line. (B) Effect of miR-203 overexpression on SkMC proliferation as assessed by MTT assay. (C) Cell cycle analysis demonstrated that G0/G1 frac-
tion was increased after miR-203 overexpression. (D, E) Apoptosis assay to investigate the population of apoptotic cells and viable cells of SkMCs after
miR-203 overexpression. Apoptosis rates were measured by annexin V and 7-amino-actinomycin D (7-AAD) staining, and apoptotic cells were calcu-
lated as upper right and lower right (D): negative control (CTRL): right panel; miR-203 mimic: left panel. Rate of apoptotic cells was signiﬁcantly in-
creased after miR-203 overexpression (P < 0.05, lower panel). The number of viable cancer cells was also calculated by MTT assay and showed
that miR-203 up-regulation decreased the number of viable SkMCs (E). (F) Prediction of miR-203 target gene via four different miRNA target prediction
tools (miRMap, Microt4, Targetscan, and RNAhybrid). (G) Expression proﬁle of apoptosis-related genes about putative targets of miR-203 showed that
overexpression of miR-203 suppressed BIRC5 expression in SkMCs. Expression proﬁle of apoptosis-related genes about putative targets of miR-203
showed that overexpression of miR-203 suppressed BIRC5 expression in SkMCs. (H) BIRC5 protein was expressed in both nucleus and cytoplasm in
SkMCs and was down-regulated in miR-203 mimic-transfected cells compared with negative CTRL cells. Each value represents the mean ± standard
error. OD, optical density.
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malignancies.10,44 Waning and co-workers established seven
different mouse models of human osteolytic bone metasta-
ses and reported impaired muscle dysfunction in these mice.
The authors performed unbiased mass spectrometry-based
screening to assess the post-transcriptional modiﬁcation of
proteins in whole skeletal muscle lysates from mice with or
without bone metastasis and found that transforming
growth factor (TGF)-β, released from the bone surface
during metastasis-induced bone destruction, could induce
oxidization of skeletal muscle proteins, impair intracellular
signalling in SkMCs, and decrease muscle contraction.10 In
line with this evidence, a recent study revealed metal-ion
transporter XRT-like and IRT-like protein 14 (ZIP14) as a criti-
cal mediator of metastatic cancer-induced cachexia.44 The au-
thors performed allografts using a metastatic subline of
mouse breast and colon cancer cell lines, and sequencing-
based comprehensive analysis using cachexic tibialis anterior
muscles showed that ZIP14 was signiﬁcantly up-regulated in
the cachexic muscles from metastatic models. ZIP14 expres-
sion was induced in SkMCs by TGF-α and TGF-β cytokines,
and ZIP14-mediated zinc uptake resulted in blocking muscle
cell differentiation and myosin heavy chain loss.44 Collec-
tively, these results suggested that metastasis-induced
sarcopenia may develop from the interaction between the
systemic circulation and the local micro-environment of skel-
etal muscle in patients with malignancies.
In contrast, as a role for miRNAs in myogenesis has been
established,45 the pivotal function of miRNAs in sarcopenia
development is also being elucidated. Connolly and col-
leagues conducted screening of miRNA expression using
quadriceps specimens from chronic obstructive lung disease
patients with or without muscle wasting and revealed that el-
evated miR-542-3p/5p induces muscle atrophy through the
promotion of mitochondrial dysfunction and activation of
SMAD2/3 phosphorylation.46 This research group then re-
cently showed that increased expression of miR-424-5p in
quadriceps is also signiﬁcantly correlated with sarcopenia
via regulation of ribosomal RNA synthesis.47 Furthermore, in
researching the function of circulating miRNAs in the patho-
genesis of cancer sarcopenia, He and colleagues demon-
strated that elevated expression of miR-21 in tumour-
secreted macrovesicles promotes myoblast apoptosis in can-
cer cachexia via a toll-like receptor 7-c-Jun N-terminal
kinase-dependent pathway.48
Combined with these data, we hypothesized that circulat-
ing miRNAs released from metastatic tissues might have the
potential to induce sarcopenia in advanced cancer patients
with distant metastasis. In this study, we performed a direct
comparison between pre-operative BC status and tissue or
serum miR-203 expression in CRC patients and revealed an
inverse correlation between PMI levels and serum miR-203
expression. Furthermore, elevated serum miR-203 levels
were an independent risk factor for low PMI (myopenia) in
CRC patients. We validated our clinical ﬁndings using a series
of in vitro analyses and demonstrated that miR-203 can in-
duce apoptosis via down-regulation of survivin in human
SkMCs. These ﬁndings help further the current research ﬁeld
of pathogenesis in metastasis-related sarcopenia in
malignancies.
Sarcopenia is generally deﬁned as a syndrome character-
ized by progressive and generalized loss of skeletal muscle
mass and strength, and the European Working Group on
Sarcopenia recommended that the deﬁnition of sarcopenia
should include both low muscle mass and low muscular func-
tion.49 Based on these recommendations, the pattern of
sarcopenia is currently divided into ‘myopenia’ and
‘myosteatosis’. Myopenia is characterized by decreased skel-
etal muscle mass irrespective of illness and ageing, and PMI is
recognized as one of representative surrogate markers for as-
sessment of skeletal muscle mass.6,50 In contrast,
myosteatosis, which is usually assessed by IMAC, is character-
ized by an increased inﬁltration of intermuscular and intra-
muscular fat.51 One of the novel ﬁndings in our study is the
intimate correlation between disease development factors
and myopenia despite the lack of those correlation with
myosteatosis in CRC patients. Furthermore, our previous
study clearly demonstrated that miR-203 could be secreted
from various metastatic tissues including lymph node, perito-
neal, and hepatic metastasis, in CRC patients.21 In contrast,
several studies indicated that intermuscular and intramuscu-
lar fatty accumulation arise through several different path-
ways, including insulin resistance, inﬂammation,
adipogenesis, inhibition of histone deacetylases, and
oestrogen deﬁciency, and suggested that these various condi-
tions might induce myosteatosis.52 Collectively, these evi-
dences with our novel ﬁnding regarding the apoptotic role
of over-expressed miR-203 in SkMCs could explain the reason
why circulating miR-203 levels signiﬁcantly correlated with
myopenia, not myosteatosis in CRC patients.
We acknowledge several potential limitations of the pres-
ent study. First, we only focused on metastatic tissues se-
creting miR-203 in this study. Further studies including a
broader, unbiased comprehensive analysis based on our con-
cept could potentially lead to the identiﬁcation of additional
secretory miRNAs to promote myopenia and cachexia in pa-
tients with various malignancies. Furthermore, unfortu-
nately, we could not assess the post-operative serum
specimens from these patients and evaluate the potential
of circulating miR-203 to monitor the status of myopenia in
CRC patients. Therefore, further studies including long-term
follow-up of BC, along with monitoring of serum miRNA,
may be needed to conﬁrm the clinical feasibility of serum
miR-203 for real-time monitoring of myopenia during peri-
operative period. Together, our results suggest that quantiﬁ-
cation of serum miR-203 expression could be used as a risk
assessment of myopenia in CRC patients and that miR-203
might be a novel therapeutic target for inhibition of
myopenia in CRC.
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